$14.04
0.342.48%
Last update: Nov 11, 3:14 PM
Alpha Tau Medical Ltd
DRTSNASDAQ
Alpha Tau Medical rose 249.5% from $3.92 to $13.70, ahead of the S&P 500's +9.8%. Its worst day was May 4 (−11.8%), and its low came Nov 20 at $3.47.
Story events cover the past 12 months · Times ET
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.14 missed the $-0.12 estimate on $0.00 revenue.
+10.1% · S&P 500 +1.0%
Alpha Tau Medical surged in after-hours trading after treating the first patient in its pilot study for recurrent glioblastoma with Alpha DaRT therapy.
+19.6% · S&P 500 +0.7%
Alpha Tau Medical shares rose 14.3%, while the S&P 500 fell 0.5%.
+14.3% · S&P 500 −0.5%
EPS of $-0.14 missed the $-0.13 estimate on $0.00 revenue.
+1.9% · S&P 500 −0.2%
Alpha Tau Medical stock surged after interim glioblastoma data showed complete responses in two patients treated with Alpha DaRT.
+21.5%, the year's best day, on 5M shares, the year's heaviest volume · S&P 500 +0.2%
EPS of $-0.26 missed the $-0.12 estimate on $0.00 revenue (est. $113,600.00).
+6.5% · S&P 500 −0.7%
- Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s commercial leadership to transform the U.S.
+18.5% · S&P 500 −0.7%
Alpha Tau Medical shares rose 14.1%, while the S&P 500 fell 1.0%.
+14.1% · S&P 500 −1.0%
EPS of $-0.50 missed the $-0.14 estimate on $0.00 revenue (est. $230,136.00).
+4.9% · S&P 500 −0.3%
Alpha Tau Medical closed at its highest level of the year, 295.4% above where the year started.
+1.7% · S&P 500 +1.6%
Where it ended: a close of $13.70 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 23, 2026 (EPS est. $-0.15, revenue est. $353,464.00).
Nothing in the past 12 months.
All DRTS dividend history
